Skip to content

Gaze Contingent Feedback in Social Anxiety Disorder

Gaze Contingent Feedback in Treatment of SAD

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02590770
Enrollment
40
Registered
2015-10-29
Start date
2015-10-31
Completion date
2016-07-31
Last updated
2016-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Phobia, Social

Brief summary

The purpose of this study is to determine whether giving gaze-contingent feedback is an effective attention modification procedure, helping in the treatment of social anxiety disorder (SAD)

Detailed description

The study examines giving social anxious participants gaze-contingent feedback as a novel attention training procedure. Half of the participants will receive contingent feedback while the other half would receive non-contingent placebo feedback.

Interventions

participants will receive gaze-continent feedback according to their viewing patterns

OTHERPlacebo

participants will receive non-gaze-continent feedback unrelated to their viewing patterns

Sponsors

Tel Aviv University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* A signed consent form * Men and women between the ages of 18 and 60. * Meeting a current diagnosis of Social Anxiety Disorder (SP) according to the DSM-IV * A minimum of a 1-year duration of SP * SP as the primary diagnosis: In cases of co-morbidity, SP will be deemed as the most distressing and clinically significant condition among the co-morbid disorders * Stable pharmaco-therapy: Participants receiving a pharmacological treatment who are taking a stable medication for at least 3 months before the beginning of the procedure.

Exclusion criteria

* Psychotic episode in the past or the present time. * Co-morbidity with any neurological disorder (i.e., epilepsy, brain injury). * Another psychotherapeutic treatment during the study. * Usage of neuroleptic medication. * Change in medication status during the study. * Substantial usage of drugs or alcohol in the present time. * Poor judgment capacity (i.e., children under 18 and special populations).

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline - the Liebowitz Social Anxiety Scale - Diagnostic Interview scorespost treatment (1 week after treatment completion) and 3-month follow upThe LSAS is a 24-item scale, each item corresponding to a situation selected on the basis of clinical experience. Each item is rated on a severity scale ranging from 0 to 3 with regard to the passing week, measuring separately two components of social anxiety, specifically, fear/anxiety and avoidance of social interaction and performance situations. Although the assessor may request and ask for further detail and adjust the rating based on clinical experience, this option is not often exercised, and inter-rater agreement is not considered to be a relevant concern. It has been shown to have strong psychometric properties, including high internal consistency, strong convergent and discriminative validity and high test-retest reliability.

Secondary

MeasureTime frameDescription
Change from baseline - the Social Phobia Inventory scorespost treatment (1 week after treatment completion) and 3-month follow upThis is a 17-item self-report measure of social anxiety evaluating fear, avoidance and physiological discomfort. Each item is rated on scale ranging from 0 to 4 with a possible total score of 68. The SPIN has been used in clinical and nonclinical samples and its psychometric properties have been found to be sound.

Other

MeasureTime frameDescription
changes in the Mini-International Neuropsychiatric Interview (M.I.N.I) diagnosispost treatment (1 week after treatment completion)a structured diagnostic interview for DSM - IV and ICD-10 psychiatric disorders, which takes approximately 20 min to administer and is a valid and time-efficient alternative to the SCID-P and CIDI.

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026